PLx Pharma, which is commercializing a delayed-release aspirin based on its proprietary lipid coating, postponed its IPO on Thursday. It had filed to raise $68 million by offering 3.8 million shares at a price range of $17 to $19. The IPO was delayed due to market conditions.
The Houston, TX-based company was founded in 2002. It had planned to list on the Nasdaq under the symbol PLXP. Raymond James and Maxim Group LLC were set to be the joint bookrunners on the deal.
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
